Chonluten

Chonluten is a synthetic tripeptide bioregulator (Glu-Asp-Gly, EDG) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, targeting the bronchial and pulmonary tissue. It is studied for its ability to modulate lung epithelial gene expression, reduce pulmonary inflammation, and regulate antioxidant defenses in the respiratory system.

Chonluten penetrates bronchial epithelial cells and translocates to the nucleus, where it directly interacts with DNA in a tissue-specific manner to modulate gene transcription patterns associated with inflammation and oxidative stress. In preclinical studies, Chonluten inhibited TNF-α production by monocytes exposed to bacterial lipopolysaccharide (LPS), demonstrating anti-inflammatory activity at the cytokine level. It modulates the expression of genes involved in antioxidant activity, mucin regulation, and bronchial epithelial barrier integrity. As with other Khavinson bioregulators, its specificity arises from the peptide's preferential interaction with promoter sequences in lung tissue cells via minor groove DNA binding, activating regenerative transcriptional programs in aged or damaged pulmonary tissue.

Research from Khavinson's group shows Chonluten's capacity to restore bronchial epithelial cell function in aged tissue models, reduce inflammatory cytokine production in stimulated human immune cell assays, and modulate antioxidant gene expression in lung tissue. Animal studies suggest protective effects in oxidative pulmonary stress models. Human research is limited to Russian clinical series. No published RCTs in the Western peer-reviewed literature exist. Preclinical findings are promising for age-related pulmonary decline but require independent replication.

Peptides commonly paired with Chonluten for synergistic effects.